



Forward-looking Statement

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

2



Summary upfront

NASH: Trials are "go ready"

An increasingly alluring potential upside

Travelan: Revenues growing and positioned to

grow further

Pipeline: Progressing

Cap Str: Robust

Financials: Debt free, cash in the bank until after

completion of NASH trial



Achievements 2014

Progress Operations	5.6.7.8.	Increase Travelan Sales & Marketing Adin Australia Launch of Travelan in Canada Progress Travelan elsewhere "Ready to start" NASH and ASH trials	ctivities 4
Improve: Financials and Capital Structure	1. 2. 3. 4.	Capital Raise: ~\$9.66M Paladin Debt Extinguished Mop Up Unmarketable Parcels Improve Hadassah royalty rates	



Robust Capital Structure

	Nov 2013	Nov/Dec 2014
Cash	• <\$1M cash at 30 Dec 13	✓ \$6M cash at 30 June 14
Debt	 CAD1.5M Paladin Debt owing 	✓ Debt Free
Share Register	 1,800 shareholders on register 	✓ ~1,200 SH following Mop Up
	Share register dispersed	✓ Top 20 own >50%
	• 3B shares on issue	✓ ~75M shares on issue*
Improved Partner Royalties	Hadasit royalty rates	✓ Improved 5 Immuron AGM
		* Pending shareholder approval Presentation



Overview, Achievements

TRAVELAN

NASH

PIPELINE

LOOKING FORWARD



Travelan® Increasing Australian Presence



7



Travelan[®] Pharmacy





Sales through pharmacies

MARKETING PROGRAM

- 1. Co-promotion
- 2. CPD Program
- 3. Guild Conference



Increasing Sales

8

Immuron AGM Presentation

Nov 2015



Travelan® **Doctors**





Sales & marketing to doctors

- 1. Specialized sales rep
- 2. Target franchised travel clinics
- 3. Engage with specialized wholesaler: Equip
- 4. Engage with KOLs
- 5. Attend Travel Medicine Conference



Immuron AGM Presentation

Nov 2015



Travelan® Online



- Upgrade: www.travelan.com.au
- 2. Online advertising
- 3. Facebook summer campaign




Online

10



Travelan® Successful Canadian Launch Exceeding Expectations



1

NASH

PIPELINE

LOOKING FORWARD




Travelan®

Status in Nov 2013 Progress in 2014 Regulatory In Market **Discussions** Term Sheet Licensed Country Canada **South Korea** Other Asian Countries **US** (partnered) No regulatory process **United States (direct)** India China

12

^{*} Regulatory application preceding partnering engagement





NASH What we have done in 2014

Appoint internal team

February 2014 Capital Raise

Formulation and manufacture of clinical trial material

C......

November 2014

Ready to start

Update

- 1. Protocol
- 2. Investigational Brochure

Select and Engage with:

- 1. Monitors
- 2. Data Management
- 3. MRI analysis (2)
- 4. Liver Biopsy
- 5. Biomarker specimens

Hospitals

- 1. Select and engage with ...
- 2. Visit/audit
- 3. Negotiate
- 4. Ethics

14

Immuron AGM Presentation

Nov 2015

Overview, Achievements

TRAVELAN


NASH/ASH


PIPELINE

LOOKING FORWARD

Immur@n

Central Co-ordination & Analysis








Sites – United States








C. Difficile

Progressing to the clinic

A promising program

Continuing Collaboration with Monash

Potential to leverage into other indications





Looking Forward 2015

Travelan	1.	Continue to increase Australian Travelan revenue	
	2.	Increase Canadian Travelan revenue	
	3.	Launch in the US	
	4.	Continue to progress elsewhere overseas	
Another Product	4.	Launch another product in Australia	
NASH	5.	Recruit patients and manage recruitment re	ate
	6.	Increase profile amongst KOLs, prospective	•
		licensees and investment community	21
C difficile	7.	Continue to progress C difficile project	Immuron AGM Presentation
			 Nov 2015

